Answers are grounded in this paper and cite their sources.
Mycobacteria contribute substantially to human infectious disease, most notably the primary pathogens of tuberculosis (TB), leprosy and Bureli ulcer. Global prospects for TB control are challenged by the emergence of drug-resistant strains. If we are to stay ahead of mycobacterial strains developing resistance to chemotherapeutic regimens, all new agent leads must be explored. Lantibiotics, either native or bio-engineered, represent one such avenue to enhance our artillery against drug-resistant strains.
No takes yet. Share an insight, caveat, or question.
John Donaghy (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: